Integrated Cognitive Behavioral Therapy for Comorbid Cannabis Use and Anxiety Disorders

Abstract

Cannabis use disorders (CUDs) co-occur with anxiety disorders at high rates, presumably because some individuals with anxiety disorders may rely on cannabis to manage anxiety. Motivation enhancement therapy (MET) combined with cognitive-behavioral therapy (CBT) is an efficacious intervention for CUD, yet outcomes are worse for patients with elevated anxiety. The integration of MET-CBT with False Safety Behavior Elimination Treatment (FSET) may be useful with anxious CUD patients, as the use of cannabis to manage anxiety can be targeted as a false safety behavior. Here, we describe the integrated treatment and the successful use of it among two patients—one with CUD and comorbid social anxiety disorder (SAD) and one with CUD and comorbid SAD and generalized anxiety disorder. Data support the feasibility of this integrated treatment as a viable approach to the treatment of CUD and comorbid anxiety disorders. Future controlled trials are now warranted to further evaluate the intervention.

Keywords

cannabis marijuana anxiety disorders dual diagnosis integrated treatment

Get full access to this article

View all access options for this article.

References

Allen

L. B.

McHugh

R. K.

Barlow

D. H.

(2008). Emotional disorders: A unified protocol. In Barlow

D. H.

(Ed.), Clinical handbook of psychology disorders: A step-by-step treatment manual (4th ed., pp. 216-249). New York, NY: Guilford Press.

American Psychiatric Association. (2000). Diagnostic and statistical manual of mental disorders (4th ed., text rev.). Washington, DC: Author.

American Psychiatric Association. (2013). Diagnostic and statistical manual of mental disorders (5th ed.). Arlington, VA: American Psychiatric Publishing.

Brown

T. A.

Antony

M. M.

Barlow

D. H.

(1992). Psychometric properties of the Penn State Worry Questionnaire in a clinical anxiety disorders sample. Behaviour Research and Therapy, 30, 33-37. doi:10.1016/0005-7967(92)90093-v

Brown

T. A.

DiNardo

P. A.

Lehman

C. L.

Campbell

L. A.

(2001). Reliability of DSM-IV anxiety and mood disorders: Implications for the classification of emotional disorders. Journal of Abnormal Psychology, 110, 49-58. doi:10.1037/0021-843X.110.1.49

Brozovich

Heimberg

R. G.

(2008). An analysis of post-event processing in social anxiety disorder. Clinical Psychology Review, 28, 891-903. doi:10.1016/j.cpr.2008.01.002

Buckner

J. D.

Carroll

K. M.

(2010). Effect of anxiety on treatment presentation and outcome: Results from the Marijuana Treatment Project. Psychiatry Research, 178, 493-500. doi:10.1016/j.psychres.2009.10.010

Buckner

J. D.

Heimberg

R. G.

Ecker

A. H.

Vinci

(2013). A biopsychosocial model of social anxiety and substance use. Depression and Anxiety, 30, 276-284. doi:10.1002/da.22032

Buckner

J. D.

Heimberg

R. G.

Matthews

R. A.

Silgado

(2012). Marijuana-related problems and social anxiety: The role of marijuana behaviors in social situations. Psychology of Addictive Behaviors, 26, 151-156. doi:10.1037/a0025822

10.

Buckner

J. D.

Heimberg

R. G.

Schneier

F. R.

Liu

Wang

Blanco

(2012). The relationship between cannabis use disorders and social anxiety disorder in the National Epidemiological Study of Alcohol and Related Conditions (NESARC). Drug and Alcohol Dependence, 124, 128-134. doi:10.1016/j.drugalcdep.2011.12.023

11.

Buckner

J. D.

Schmidt

N. B.

(2009). A randomized pilot study of motivation enhancement therapy to increase utilization of cognitive–behavioral therapy for social anxiety. Behaviour Research and Therapy, 47, 710-715. doi:10.1016/j.brat.2009.04.009

12.

Buckner

J. D.

Schmidt

N. B.

Bobadilla

Taylor

(2006). Social anxiety and problematic cannabis use: Evaluating the moderating role of stress reactivity and perceived coping. Behaviour Research and Therapy, 44, 1007-1015.

13.

Buckner

J. D.

Schmidt

N. B.

Lang

A. R.

Small

J. W.

Schlauch

R. C.

Lewinsohn

P. M.

(2008). Specificity of social anxiety disorder as a risk factor for alcohol and cannabis dependence. Journal of Psychiatric Research, 42, 230-239. doi:10.1016/j.jpsychires.2007.01.002

14.

Buckner

J. D.

Zvolensky

M. J.

Ecker

A. H.

(2013). Cannabis use during a voluntary quit attempt: An analysis from ecological momentary assessment. Drug and Alcohol Dependence, 132, 610-616. doi:10.1016/j.drugalcdep.2013.04.013

15.

Buckner

J. D.

Zvolensky

M. J.

Schmidt

N. B.

Carroll

K. M.

Schatschneider

Crapanzano

(2014). Integrated cognitive behavioral therapy for cannabis use and anxiety disorders: Rationale and development. Addictive Behaviors, 39, 495-496. doi:10.1016/j.addbeh.2013.10.023

16.

Cougle

J. R.

Hakes

J. K.

Macatee

R. J.

Zvolensky

M. J.

Chavarria

(in press). Probability and correlates of dependence among regular users of alcohol, nicotine, cannabis, and cocaine: Concurrent and prospective analyses of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). Journal of Clinical Psychiatry.

17.

Courbasson

C. M.

Nishikawa

(2010). Cognitive behavioral group therapy for patients with co-existing social anxiety disorder and substance use disorders: A pilot study. Cognitive Therapy and Research, 34, 82-91. doi:10.1007/s10608-008-9216-8

18.

DiNardo

Brown

Barlow

(1994). Anxiety Disorders Interview Schedule for DSM-IV: Lifetime Version (ADIS-IV-L). New York, NY: Oxford University Press.

19.

Fals-Stewart

O’Farrell

T. J.

Freitas

T. T.

McFarlin

S. K.

Rutigliano

(2000). The Timeline Followback reports of psychoactive substance use by drug-abusing patients: Psychometric properties. Journal of Consulting and Clinical Psychology, 68, 134-144. doi:10.1037/0022-006x.68.1.134

20.

First

M. B.

Spitzer

R. L.

Gibbon

Williams

J. B. W.

(2007). Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition With Psychotic Screen (SCID-I/P W/PSY SCREEN). New York: Biometrics Research, New York State Psychiatric Institute.

21.

Heimberg

R. G.

(2002). Cognitive–behavioral therapy for social anxiety disorder: Current status and future directions. Biological Psychiatry, 51, 101-108. doi:10.1016/S0006-3223(01)01183-0

22.

Heimberg

R. G.

Mueller

G. P.

Holt

C. S.

Hope

D. A.

Liebowitz

M. R.

(1992). Assessment of anxiety in social interaction and being observed by others: The Social Interaction Anxiety Scale and the Social Phobia Scale. Behavior Therapy, 23, 53-73. doi:10.1016/S0005-7894(05)80308-9

23.

Mattick

R. P.

Clarke

J. C.

(1998). Development and validation of measures of social phobia scrutiny fear and social interaction anxiety. Behaviour Research and Therapy, 36, 455-470. doi:10.1016/s0005-7967(97)10031-6

24.

Meyer

T. J.

Miller

M. L.

Metzger

R. L.

Borkovec

T. D.

(1990). Development and validation of the Penn State Worry Questionnaire. Behaviour Research and Therapy, 28, 487-495. doi:10.1016/0005-7967(90)90135-6

25.

Molina

Borkovec

T. D.

(1994). The Penn State Worry Questionnaire: Psychometric properties and associated characteristics. In Davey

G. C. L.

Tallis

(Eds.), Worrying: Perspectives on theory, assessment and treatment (pp. 265-283). Oxford, UK: John Wiley.

26.

Moore

B. A.

Budney

A. J.

(2003). Relapse in outpatient treatment for marijuana dependence. Journal of Substance Abuse Treatment, 25, 85-89. doi:10.1016/S0740-5472(03)00083-7

27.

National Institute of Drug Abuse. (2010). Strategic plan. Retrieved from http://www.drugabuse.gov/about-nida/2010-strategic-plan

28.

Salkovskis

P. M.

Clark

D. M.

Hackmann

(1991). Treatment of panic attacks using cognitive therapy without exposure or breathing retraining. Behaviour Research and Therapy, 29, 161-166. doi:10.1016/0005-7967(91)90044-4

29.

Schmidt

N. B.

Buckner

J. D.

Pusser

A. T.

Woolaway-Bickel

Preston

J. L.

(2012). Randomized controlled trial of False Safety Behavior Elimination Therapy (F-SET): A unified cognitive behavioral treatment for anxiety psychopathology. Behavior Therapy, 43, 518-532. doi:10.1016/j.beth.2012.02.004

30.

Sobell

L. C.

Sobell

M. B.

(1996). Timeline FollowBack user’s guide: A calendar method for assessing alcohol and drug use. Toronto: Addiction Research Foundation.

31.

Steinberg

K. L.

Roffman

R. A.

Carroll

K. M.

McRee

Babor

T. F.

Miller

. . .Stephens

(2005). Brief counseling for marijuana dependence: A manual for treating adults (DHHS Publication No. (SMA) 05-4022). Rockville, MD: Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration.

32.

Stewart

S. H.

Conrod

P. J.

(2008). Anxiety disorder and substance use disorder co-morbidity: Common themes and future directions. In Stewart

S. H.

Conrod

P. J.

(Eds.), Anxiety and substance use disorders: The vicious cycle of comorbidity (pp. 239-257). New York, NY: Springer. doi:10.1007/978-0-387-74290-8_13

33.

Stinson

F. S.

Grant

B. F.

Dawson

D. A.

Ruan

W. J.

Huang

Saha

(2006). Comorbidity between DSM-IV alcohol and specific drug use disorders in the United States: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. Alcohol Research & Health, 29, 94-106.

34.

Stinson

F. S.

Ruan

W. J.

Pickering

Grant

B. F.

(2006). Cannabis use disorders in the USA: Prevalence, correlates, and co-morbidity. Psychological Medicine, 36, 1447-1460. doi:10.1017/s0033291706008361

35.

Watson

O’Hara

M. W.

Simms

L. J.

Kotov

Chmielewski

McDade-Montez

E. A.

. . . Stuart

(2007). Development and validation of the Inventory of Depression and Anxiety Symptoms (IDAS). Psychological Assessment, 19, 253-268. doi:10.1037/1040-3590.19.3.253

36.

Westra

H. A.

Arkowitz

Dozois

D. J. A.

(2009). Adding a motivational interviewing pretreatment to cognitive behavioral therapy for generalized anxiety disorder: A preliminary randomized controlled trial. Journal of Anxiety Disorders, 23, 1106-1117. doi:10.1016/j.janxdis.2009.07.014

37.

Zvolensky

M. J.

Marshall

E. C.

Johnson

Hogan

Bernstein

Bonn-Miller

M. O.

(2009). Relations between anxiety sensitivity, distress tolerance, and fear reactivity to bodily sensations to coping and conformity marijuana use motives among young adult marijuana users. Experimental and Clinical Psychopharmacology, 17, 31-42. doi:10.1037/a0014961